Regulus Therapeutics Inc.
RGLS
Classement en actions
#17329
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Prix de l'action
$8.16
Dernière synchronisation: 2025-06-26
Capitalisation boursière
$234.57M
Changement (1 jour)
0.00%
Changement (1 an)
-56.96%
Pays
US
Échange Regulus Therapeutics Inc. (RGLS)
Catégorie
Healthcare
Nombre d'actions en circulation pour Regulus Therapeutics Inc. (RGLS)
Nombre d'actions en circulation au March 2024: 150.47M
Selon les derniers rapports financiers et le cours de l'action de Regulus Therapeutics Inc., le nombre actuel d'actions en circulation est de 150.47M. À la fin de December 2022, l'entreprise avait 136.62M actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Regulus Therapeutics Inc. (RGLS) de 2002 à 2026
Actions en circulation à la fin de chaque année
| Année | Actions en circulation | Changez |
|---|---|---|
| 2026 (TTM) | 150.47M | 9.64% |
| 2023 | 137.24M | 0.45% |
| 2022 | 136.62M | 2.26% |
| 2021 | 133.60M | 1.37% |
| 2020 | 131.79M | 4.27% |
| 2019 | 126.40M | 0.83% |
| 2018 | 125.36M | 8.26% |
| 2017 | 115.79M | 9.47% |
| 2016 | 105.77M | 1.15% |
| 2015 | 104.57M | 4.13% |
| 2014 | 100.42M | 2.18% |
| 2013 | 98.28M | 3.83% |
| 2012 | 94.65M | -74.15% |
| 2011 | 366.20M | 1.02% |
| 2010 | 362.50M | 0.85% |
| 2009 | 359.44M | 1.12% |
| 2008 | 355.47M | 4.07% |
| 2007 | 341.56M | 11.55% |
| 2006 | 306.19M | 14.34% |
| 2005 | 267.79M | 8.72% |
| 2004 | 246.31M | 18.44% |
| 2003 | 207.96M | 12.86% |
| 2002 | 184.26M | 0.00% |
Actions en circulation pour des entreprises similaires ou concurrentes
| Entreprise | Actions en circulation | Différence | Pays |
|---|---|---|---|
| 253.90M | 68.74% |
US
|
|
| 396.00M | 163.17% |
US
|
|
| 478.91M | 218.27% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -58.67% |
NL
|
